Renin-angiotensin-system-acting agents for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo
vs. standard of care
vs. miscellaneous
vs. calcium channel blocker
vs. Renin-angiotensin-system-acting agents
vs. continuation of ACEI/ARB

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

University of Minnesota, 2021 NCT04311177

angiotensin receptor blockers (ARBs) (n=58) vs. placebo (n=59)

randomized controlled trial

Studied treatment

Losartan
Losartan 25 mg orally twice daily unless estimated glomerular filtration rate, eGFR, was reduced, when dosing was reduced to once daily.

Control treatment

Placebo

Patients

COVID 19 outpatients

presumptive positive laboratory test for SARS-coV-2 or upper respiratory infection with recent exposure to laboratory-proven SARS-coV-2-infected personnegative influenza and respiratory virus panel

Method

Double-blind.

3 hospitals in Minnesota, United States.

Remark

ACEI-COVID (Bauer), 2021 NCT04353596

discontinuation of ACEI/ARB (n=104) vs. continuation of ACEI/ARB (n=100)

randomized controlled trial

Studied treatment

discontinuation of RAS inhibition

Control treatment

continuation of RAS inhibition

Patients

COVID 19 outpatients

Method

open-label

35 centres in Austria and Germany

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open